Healthcare / Medical Instruments & SuppliesNasdaqGS
$10.91
-0.57 (-4.97%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 23%
FCF escenarios
weak_data · normalized FCF $-14.6M · quality 30.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
13/100
F
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$451M
P/E
N/A
•EV/EBITDA
224.3x
↑ROE
-18.6%
↓Gross Margin
53.9%
↑Debt/Equity
N/A
•TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2010–2025 · 15 años de histórico normalizado
Revenue CAGR
+2.0%
FCF CAGR
—
FCF margin
-5.0%
FCF / Net income
0.43x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $292.5M · net income $-34.0M · FCF $-14.6M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||||||||
| Revenue | $292.5M | $292.5M | $303.9M | $338.8M | $316.2M | $291.0M | $264.2M | $270.6M | $261.7M | $349.6M | $353.9M | — | — | $341.9M | $221.9M | $215.6M | $216.0M |
| Net Income | $-34.0M | $-34.0M | $-184.3M | $-52.4M | $-26.5M | $-31.5M | $-166.8M | $61.3M | $16.3M | $5.0M | $-43.6M | — | — | $-1.1M | $-5.3M | $8.1M | $12.3M |
| EBITDA | $1.7M | $1.7M | $-6.1M | $12.2M | $11.1M | $-9.4M | $-143.3M | $16.5M | $9.0M | $13.6M | $29.1M | — | — | $32.5M | $9.4M | $24.5M | $33.3M |
| EPS | -0.83 | -0.83 | -4.59 | -1.33 | -0.68 | -0.82 | -4.39 | 1.64 | 0.44 | 0.14 | -1.21 | — | — | -0.03 | -0.20 | 0.32 | 0.50 |
| Gross Margin | 53.9% | 53.9% | 50.9% | 51.4% | 52.4% | 53.9% | 56.9% | 57.6% | 55.0% | 41.2% | 49.3% | — | — | 49.3% | 56.5% | 58.2% | 58.8% |
| Operating Margin | -8.2% | -8.2% | -11.1% | -5.5% | -5.8% | -12.1% | -63.3% | -3.5% | -5.4% | -3.2% | 0.3% | — | — | 1.5% | -2.4% | 5.5% | 9.7% |
| Net Margin | -11.6% | -11.6% | -60.7% | -15.5% | -8.4% | -10.8% | -63.1% | 22.7% | 6.2% | 1.4% | -12.3% | — | — | -0.3% | -2.4% | 3.7% | 5.7% |
| Balance Sheet | |||||||||||||||||
| Debt/Equity | — | — | 0.02 | 0.17 | 0.08 | — | — | 0.20 | 0.16 | 0.18 | — | — | — | 0.26 | 0.27 | 0.02 | — |
| Current Ratio | 2.35 | 2.35 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Cash Flow | |||||||||||||||||
| Free Cash Flow | $-14.6M | $-14.6M | $-33.9M | $-4.3M | $-11.5M | $18.9M | $-21.8M | $34.3M | $38.9M | $52.7M | $42.9M | — | — | $14.5M | $9.1M | $30.9M | $34.9M |
| Returns | |||||||||||||||||
| ROE | -18.6% | -18.6% | -89.7% | -13.9% | -6.3% | -7.2% | -36.7% | 10.0% | 3.0% | 1.0% | -8.6% | — | — | -0.2% | -1.0% | 2.0% | 3.1% |
| Valuation | |||||||||||||||||
| EV/EBITDA | 224.29 | 224.29 | — | 33.95 | 71.27 | — | — | — | — | — | — | — | — | — | — | — | — |
| P/B | 2.44 | 2.44 | 1.22 | 1.04 | 1.86 | — | — | — | — | — | — | — | — | — | — | — | — |
| Growth & Yield | |||||||||||||||||
| Revenue Growth | -3.8% | -3.8% | -10.3% | 7.1% | — | 10.2% | -2.4% | 3.4% | -25.2% | -1.2% | — | — | — | 54.1% | 2.9% | -0.2% | — |
| EPS Growth | 81.9% | 81.9% | -245.1% | -95.6% | — | 81.3% | -367.7% | 272.7% | 214.3% | 111.6% | — | — | — | 85.0% | -162.5% | -36.0% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+7.0%
Start / end P/E
n/dx → n/dx
EPS bridge
-4.59 → -0.83
Residual
+7.0%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.